new ORAL agent for rheumatoid arthritis, Xeljanz (ZEL-jans, tofacitinib)

January 2013

You'll hear about a new ORAL agent for rheumatoid arthritis, Xeljanz (ZEL-jans, tofacitinib).

Xeljanz is the first Janus kinase (JAK) inhibitor. Janus kinases are enzymes linked to inflammation in joints and other tissues.

It's not a first-line agent. It's for patients who have failed or can't tolerate methotrexate.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote